A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Top Cited Papers
- 1 October 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (14) , 1339-1348
Abstract
It is uncertain whether treatment of mild gestational diabetes mellitus improves pregnancy outcomes. Women who were in the 24th to 31st week of gestation and who met the criteria for mild gestational diabetes mellitus (i.e., an abnormal result on an oral glucose-tolerance test but a fasting glucose level below 95 mg per deciliter [5.3 mmol per liter]) were randomly assigned to usual prenatal care (control group) or dietary intervention, self-monitoring of blood glucose, and insulin therapy, if necessary (treatment group). The primary outcome was a composite of stillbirth or perinatal death and neonatal complications, including hyperbilirubinemia, hypoglycemia, hyperinsulinemia, and birth trauma. A total of 958 women were randomly assigned to a study group — 485 to the treatment group and 473 to the control group. We observed no significant difference between groups in the frequency of the composite outcome (32.4% and 37.0% in the treatment and control groups, respectively; P=0.14). There were no perinatal deaths. However, there were significant reductions with treatment as compared with usual care in several prespecified secondary outcomes, including mean birth weight (3302 vs. 3408 g), neonatal fat mass (427 vs. 464 g), the frequency of large-for-gestational-age infants (7.1% vs. 14.5%), birth weight greater than 4000 g (5.9% vs. 14.3%), shoulder dystocia (1.5% vs. 4.0%), and cesarean delivery (26.9% vs. 33.8%). Treatment of gestational diabetes mellitus, as compared with usual care, was also associated with reduced rates of preeclampsia and gestational hypertension (combined rates for the two conditions, 8.6% vs. 13.6%; P=0.01). Although treatment of mild gestational diabetes mellitus did not significantly reduce the frequency of a composite outcome that included stillbirth or perinatal death and several neonatal complications, it did reduce the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and hypertensive disorders. (ClinicalTrials.gov number, NCT00069576.)Keywords
This publication has 35 references indexed in Scilit:
- The Hyperglycemia and Adverse Pregnancy Outcomes trial: answers but still more questions about the management of gestational diabetesDiabetic Medicine, 2008
- Nutrition Recommendations and Interventions for DiabetesDiabetes Care, 2008
- Childhood Obesity and Metabolic ImprintingDiabetes Care, 2007
- Gestational diabetes: The consequences of not treatingAmerican Journal of Obstetrics and Gynecology, 2005
- Screening for gestational diabetes: a summary of the evidence for the U.S. Preventive Services Task ForceObstetrics & Gynecology, 2003
- First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Gestational Diabetes: Risk or Myth?The Journal of Clinical Endocrinology & Metabolism, 1999
- Cesarean delivery in relation to birth weight and gestational glucose tolerance: pathophysiology or practice style? Toronto Trihospital Gestational Diabetes InvestigatorsJAMA, 1996
- Anthropometric estimation of neonatal body compositionAmerican Journal of Obstetrics and Gynecology, 1995
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983